Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group ALC.2 (CALGB 10603) -- A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) or Placebo in Newly-Diagnosed Patients <60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) -- has met its accrual goal and therefore:

PRE-REGISTRATION closed on Monday, 10 October 2011.

REGISTRATION/RANDOMIZATION closed on Saturday, 15 October 2011.

Thanks to all participating centres, staff and patients for their participation in this trial.